Decreased PU.1 expression in mature B cells induces lymphomagenesis.

IF 5.7 2区 医学 Q1 Medicine Cancer Science Pub Date : 2024-09-25 DOI:10.1111/cas.16344
Shinya Endo, Nao Nishimura, Kosuke Toyoda, Yoshihiro Komohara, Joaquim Carreras, Hiromichi Yuki, Takafumi Shichijo, Shikiko Ueno, Niina Ueno, Shinya Hirata, Yawara Kawano, Kisato Nosaka, Masashi Miyaoka, Naoya Nakamura, Ai Sato, Kiyoshi Ando, Hiroaki Mitsuya, Koichi Akashi, Daniel G Tenen, Jun-Ichirou Yasunaga, Masao Matsuoka, Yutaka Okuno, Hiro Tatetsu
{"title":"Decreased PU.1 expression in mature B cells induces lymphomagenesis.","authors":"Shinya Endo, Nao Nishimura, Kosuke Toyoda, Yoshihiro Komohara, Joaquim Carreras, Hiromichi Yuki, Takafumi Shichijo, Shikiko Ueno, Niina Ueno, Shinya Hirata, Yawara Kawano, Kisato Nosaka, Masashi Miyaoka, Naoya Nakamura, Ai Sato, Kiyoshi Ando, Hiroaki Mitsuya, Koichi Akashi, Daniel G Tenen, Jun-Ichirou Yasunaga, Masao Matsuoka, Yutaka Okuno, Hiro Tatetsu","doi":"10.1111/cas.16344","DOIUrl":null,"url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma, accounting for 30% of non-Hodgkin lymphomas. Although comprehensive analysis of genetic abnormalities has led to the classification of lymphomas, the exact mechanism of lymphomagenesis remains elusive. The Ets family transcription factor, PU.1, encoded by Spi1, is essential for the development of myeloid and lymphoid cells. Our previous research illustrated the tumor suppressor function of PU.1 in classical Hodgkin lymphoma and myeloma cells. In the current study, we found that patients with DLBCL exhibited notably reduced PU.1 expression in their lymphoma cells, particularly in the non-germinal center B-cell-like (GCB) subtype. This observation suggests that downregulation of PU.1 may be implicated in DLBCL tumor growth. To further assess PU.1's role in mature B cells in vivo, we generated conditional Spi1 knockout mice using Cγ1-Cre mice. Remarkably, 13 of the 23 knockout mice (56%) showed splenomegaly, lymphadenopathy, or masses, with some having histologically confirmed B-cell lymphomas. In contrast, no wild-type mice developed B-cell lymphoma. In addition, RNA-seq analysis of lymphoma cells from Cγ1-Cre Spi1<sup>F/F</sup> mice showed high frequency of each monoclonal CDR3 sequence, indicating that these lymphoma cells were monoclonal tumor cells. When these B lymphoma cells were transplanted into immunodeficient recipient mice, all mice died within 3 weeks. Lentiviral-transduced Spi1 rescued 60% of the recipient mice, suggesting that PU.1 has a tumor suppressor function in vivo. Collectively, PU.1 is a tumor suppressor in mature B cells, and decreased PU.1 results in mature B-cell lymphoma development.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cas.16344","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma, accounting for 30% of non-Hodgkin lymphomas. Although comprehensive analysis of genetic abnormalities has led to the classification of lymphomas, the exact mechanism of lymphomagenesis remains elusive. The Ets family transcription factor, PU.1, encoded by Spi1, is essential for the development of myeloid and lymphoid cells. Our previous research illustrated the tumor suppressor function of PU.1 in classical Hodgkin lymphoma and myeloma cells. In the current study, we found that patients with DLBCL exhibited notably reduced PU.1 expression in their lymphoma cells, particularly in the non-germinal center B-cell-like (GCB) subtype. This observation suggests that downregulation of PU.1 may be implicated in DLBCL tumor growth. To further assess PU.1's role in mature B cells in vivo, we generated conditional Spi1 knockout mice using Cγ1-Cre mice. Remarkably, 13 of the 23 knockout mice (56%) showed splenomegaly, lymphadenopathy, or masses, with some having histologically confirmed B-cell lymphomas. In contrast, no wild-type mice developed B-cell lymphoma. In addition, RNA-seq analysis of lymphoma cells from Cγ1-Cre Spi1F/F mice showed high frequency of each monoclonal CDR3 sequence, indicating that these lymphoma cells were monoclonal tumor cells. When these B lymphoma cells were transplanted into immunodeficient recipient mice, all mice died within 3 weeks. Lentiviral-transduced Spi1 rescued 60% of the recipient mice, suggesting that PU.1 has a tumor suppressor function in vivo. Collectively, PU.1 is a tumor suppressor in mature B cells, and decreased PU.1 results in mature B-cell lymphoma development.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
成熟 B 细胞中 PU.1 表达减少会诱发淋巴瘤。
弥漫大 B 细胞淋巴瘤(DLBCL)是淋巴瘤中最常见的亚型,占非霍奇金淋巴瘤的 30%。虽然对基因异常的全面分析已促成了淋巴瘤的分类,但淋巴瘤发生的确切机制仍难以确定。Spi1编码的Ets家族转录因子PU.1对髓系细胞和淋巴细胞的发育至关重要。我们之前的研究表明,PU.1 在经典霍奇金淋巴瘤和骨髓瘤细胞中具有肿瘤抑制功能。在目前的研究中,我们发现DLBCL患者的淋巴瘤细胞中PU.1的表达明显减少,尤其是在非生殖中心B细胞样(GCB)亚型中。这一观察结果表明,PU.1 的下调可能与 DLBCL 肿瘤的生长有关。为了进一步评估PU.1在体内成熟B细胞中的作用,我们利用Cγ1-Cre小鼠产生了条件性Spi1基因敲除小鼠。值得注意的是,23 只基因敲除小鼠中有 13 只(56%)出现脾脏肿大、淋巴结病变或肿块,其中一些经组织学证实患有 B 细胞淋巴瘤。相比之下,野生型小鼠没有出现 B 细胞淋巴瘤。此外,对来自 Cγ1-Cre Spi1F/F 小鼠的淋巴瘤细胞进行的 RNA-seq 分析显示,每个单克隆 CDR3 序列的频率都很高,表明这些淋巴瘤细胞是单克隆肿瘤细胞。将这些 B 淋巴瘤细胞移植到免疫缺陷受体小鼠体内,所有小鼠均在 3 周内死亡。慢病毒转导的 Spi1 挽救了 60% 的受体小鼠,表明 PU.1 在体内具有肿瘤抑制功能。综上所述,PU.1是成熟B细胞的肿瘤抑制因子,PU.1的减少会导致成熟B细胞淋巴瘤的发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Science
Cancer Science ONCOLOGY-
CiteScore
9.90
自引率
3.50%
发文量
406
审稿时长
17 weeks
期刊介绍: Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
期刊最新文献
Fibrocytes in tumor microenvironment: Identification of their fraction and novel therapeutic strategy. The prognostic significance of MYC/BCL2 double expression in DLBCL in the genetic classification era. METTL14 attenuates cancer stemness by suppressing ATF5/WDR74/β-catenin axis in gastric cancer. Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers. Integrated machine learning to predict the prognosis of lung adenocarcinoma patients based on SARS-COV-2 and lung adenocarcinoma crosstalk genes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1